NCT02249221View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent cell-culture based influenza vaccin

GC3106, 0.5ml, intramuscular, a single dosing at Day 1

BIOLOGICAL

Trivalent influenza vaccine

GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT02249221 - Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine) | Biotech Hunter | Biotech Hunter